Kanvas Biosciences Introduces New Drug Candidate in its Immuno-oncology Program

KAN-003 seeks to improve outcomes for patients with ICI-naive cancers and is undergoing preclinical studies in collaboration with the MD Anderson Cancer Center. PRINCETON, N.J., June 20, 2024 /PRNewswire/ — Kanvas Biosciences, a full-stack spatial biology company, today introduced its…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.